BACKGROUND AND PURPOSE: Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), are inflammatory demyelinating diseases that develop as a result of deregulated immune responses causing glial activation and destruction of CNS tissues. Oleanolic acid and erythrodiol are natural triterpenes that display strong anti-inflammatory and immunomodulatory activities. Oleanolic acid beneficially influences the course of established EAE. We now extend our previous observations to erythrodiol and address the efficacy of both compounds to protect against EAE, given under different regimens. EXPERIMENTAL APPROACH: The utility of both triterpenes in disease prevention was evaluated at a clinical and molecular level: in vivo through their prophylactic administration to myelin oligodendrocyte protein-immunized C57BL/6 mice, and in vitro through their addition to stimulated-BV2 microglial cells. KEY RESULTS: These triterpenes protected against EAE by restricting infiltration of inflammatory cells into the CNS and by preventing blood-brain barrier disruption. Triterpene-pretreated EAE-mice exhibited less leptin secretion, and switched cytokine production towards a Th2/regulatory profile, with lower levels of Th1 and Th17 cytokines and higher expression of Th2 cytokines in both serum and spinal cord. Triterpenes also affected the humoral response causing auto-antibody production inhibition. In vitro, triterpenes inhibited ERK and rS6 phosphorylation and reduced the proliferative response, phagocytic properties and synthesis of proinflammatory mediators induced by the addition of inflammatory stimuli to microglia. CONCLUSIONS AND IMPLICATIONS: Both triterpenes restricted the development of the characteristic features of EAE. We envision these natural products as novel helpful tools for intervention in autoimmune and neurodegenerative diseases including MS.
BACKGROUND AND PURPOSE:Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), are inflammatory demyelinating diseases that develop as a result of deregulated immune responses causing glial activation and destruction of CNS tissues. Oleanolic acid and erythrodiol are natural triterpenes that display strong anti-inflammatory and immunomodulatory activities. Oleanolic acid beneficially influences the course of established EAE. We now extend our previous observations to erythrodiol and address the efficacy of both compounds to protect against EAE, given under different regimens. EXPERIMENTAL APPROACH: The utility of both triterpenes in disease prevention was evaluated at a clinical and molecular level: in vivo through their prophylactic administration to myelin oligodendrocyte protein-immunized C57BL/6 mice, and in vitro through their addition to stimulated-BV2 microglial cells. KEY RESULTS: These triterpenes protected against EAE by restricting infiltration of inflammatory cells into the CNS and by preventing blood-brain barrier disruption. Triterpene-pretreated EAE-mice exhibited less leptin secretion, and switched cytokine production towards a Th2/regulatory profile, with lower levels of Th1 and Th17 cytokines and higher expression of Th2 cytokines in both serum and spinal cord. Triterpenes also affected the humoral response causing auto-antibody production inhibition. In vitro, triterpenes inhibited ERK and rS6 phosphorylation and reduced the proliferative response, phagocytic properties and synthesis of proinflammatory mediators induced by the addition of inflammatory stimuli to microglia. CONCLUSIONS AND IMPLICATIONS: Both triterpenes restricted the development of the characteristic features of EAE. We envision these natural products as novel helpful tools for intervention in autoimmune and neurodegenerative diseases including MS.
Authors: N Suh; T Honda; H J Finlay; A Barchowsky; C Williams; N E Benoit; Q W Xie; C Nathan; G W Gribble; M B Sporn Journal: Cancer Res Date: 1998-02-15 Impact factor: 12.701
Authors: Mustafa G Mujtaba; Lawrence O Flowers; Chintak B Patel; Ravi A Patel; Mohammad I Haider; Howard M Johnson Journal: J Immunol Date: 2005-10-15 Impact factor: 5.422
Authors: Frank L Heppner; Melanie Greter; Denis Marino; Jeppe Falsig; Gennadij Raivich; Nadine Hövelmeyer; Ari Waisman; Thomas Rülicke; Marco Prinz; Josef Priller; Burkhard Becher; Adriano Aguzzi Journal: Nat Med Date: 2005-01-23 Impact factor: 53.440
Authors: Veronica De Rosa; Claudio Procaccini; Antonio La Cava; Paolo Chieffi; Giovanni Francesco Nicoletti; Silvia Fontana; Serafino Zappacosta; Giuseppe Matarese Journal: J Clin Invest Date: 2006-01-12 Impact factor: 14.808
Authors: Hlengiwe P Madlala; Thomas Metzinger; Fanie R van Heerden; Cephas T Musabayane; Kanigula Mubagwa; Chantal Dessy Journal: PLoS One Date: 2016-01-22 Impact factor: 3.240